Home » Stocks » NH

NantHealth, Inc. (NH)

Stock Price: $3.72 USD -0.04 (-1.06%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $3.71 -0.01 (-0.27%) Jan 21, 5:16 PM
Market Cap 415.94M
Revenue (ttm) 78.72M
Net Income (ttm) -47.97M
Shares Out 110.93M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $3.72
Previous Close $3.76
Change ($) -0.04
Change (%) -1.06%
Day's Open 3.77
Day's Range 3.68 - 3.85
Day's Volume 823,288
52-Week Range 1.11 - 5.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 4 weeks ago

Investors need to pay close attention to NantHealth (NH) stock based on the movements in the options market lately.

Business Wire - 1 month ago

EL SEGUNDO, Calif. & SAN ANTONIO, Texas--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights...

Business Wire - 2 months ago

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insight...

Seeking Alpha - 2 months ago

NantHealth, Inc. (NH) Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio on S...

Business Wire - 3 months ago

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced a series of secure Application Programm...

Business Wire - 3 months ago

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the national rollout of NaviNet AllPayer, a s...

Seeking Alpha - 5 months ago

NantHealth, Inc. (NH) Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

NantHealth, Inc. (NH) delivered earnings and revenue surprises of -16.67% and -3.38%, respectively, for the quarter ended June 2020.

Business Wire - 5 months ago

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc.

Seeking Alpha - 6 months ago

NantHealth Points To The Future Of Healthcare

Business Wire - 6 months ago

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the publication of a study in JCI Insig...

Zacks Investment Research - 7 months ago

NantHealth (NH) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Seeking Alpha - 8 months ago

NantHealth, Inc. (NH) Management on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

NantHealth Inc (NH) delivered earnings and revenue surprises of 14.29% and -5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

InvestorPlace - 8 months ago

These exciting stocks to buy for aggressive investors might be small, but they have massive growth potential when the pandemic clears up. The post 7 Top Stocks to Buy for Aggressive Investor...

Other stocks mentioned: DRD, ENPH, IFMK, OESX, XBIT
Seeking Alpha - 10 months ago

NantHealth, Inc. (NH) CEO Dr.

Market Watch - 11 months ago

Shares of NantHealth Inc. soared 56% in premarket trading on Tuesday after the company said it had developed an artificial intelligence software used to improve lung-cancer diagnoses.

Seeking Alpha - 1 year ago

NantHealth Scores Milestone FDA Approval While SaaS Business Grows

Seeking Alpha - 1 year ago

NantHealth, Inc. (NH) CEO Patrick Soon Shiong on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

NantHealth, Inc. (NH) delivered earnings and revenue surprises of -75.00% and -4.46%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

NantHealth's (NH) CEO Patrick Soon-Shiong on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

NantHealth, Inc. (NH) delivered earnings and revenue surprises of 55.56% and 7.03%, respectively, for the quarter ended June 2019.

Zacks Investment Research - 1 year ago

NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

NantHealth, Inc. (NH) CEO Patrick Soon-Shiong on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

NantHealth's (NH) CEO Patrick Soon-Shiong on Q4 2018 Results - Earnings Call Transcript

About NH

NantHealth, together with its subsidiaries, operates as a healthcare technology company converging science and technology in the United States, the United Kingdom, Singapore, and Canada. It provides NantHealth solutions, including molecular profiling solutions, software-as-a-service platforms, and connected care medical device interoperability solutions to enable value-based care and evidence-based clinical practice. The company's products include GPS Cancer, a molecular profile that integrates whole genome/exome sequencing of tumor and normal ... [Read more...]

Industry
Health Information Services
IPO Date
Jun 2, 2016
CEO
Patrick Soon-Shiong
Employees
398
Stock Exchange
NASDAQ
Ticker Symbol
NH
Full Company Profile

Financial Performance

In 2019, NantHealth's revenue was $95.96 million, an increase of 7.26% compared to the previous year's $89.46 million. Losses were -$62.76 million, -67.34% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for NantHealth stock is "Strong Buy." The 12-month stock price forecast is 3.75, which is an increase of 0.81% from the latest price.

Price Target
$3.75
(0.81% upside)
Analyst Consensus: Strong Buy